Agalsidase alfa: specific treatment for Fabry disease
- 1 June 2002
- journal article
- review article
- Published by Mark Allen Group in Hospital Medicine
- Vol. 63 (6), 347-350
- https://doi.org/10.12968/hosp.2002.63.6.2005
Abstract
Fabry disease is a rare genetic lysosomal storage disorder characterized by a deficiency of the enzyme a-galactosidase A. The recent availability of enzyme-replacement therapy with agalsidase alfa offers specific treatment for this serious, progressive condition.Keywords
This publication has 14 references indexed in Scilit:
- Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous malesJournal of Medical Genetics, 2001
- Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's DiseaseNew England Journal of Medicine, 2001
- Anderson-Fabry's disease: α galactosidase deficiencyThe Lancet, 2001
- Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry diseaseProceedings of the National Academy of Sciences of the United States of America, 2000
- The frequency of lysosomal storage diseases in The NetherlandsHuman Genetics, 1999
- An Atypical Variant of Fabry's Disease in Men with Left Ventricular HypertrophyNew England Journal of Medicine, 1995
- Psychiatric Disorders in Patients with Fabry's DiseaseThe International Journal of Psychiatry in Medicine, 1993
- Anderson-Fabry disease.BMJ, 1988
- The Ocular Manifestations in Fabry's DiseaseAmerican Journal of Ophthalmology, 1979
- Gene Action in the X-chromosome of the Mouse (Mus musculus L.)Nature, 1961